» Articles » PMID: 32241281

Disruption of the RNA Modifications That Target the Ribosome Translation Machinery in Human Cancer

Overview
Journal Mol Cancer
Publisher Biomed Central
Date 2020 Apr 4
PMID 32241281
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Genetic and epigenetic changes deregulate RNA and protein expression in cancer cells. In this regard, tumors exhibit an abnormal proteome in comparison to the corresponding normal tissues. Translation control is a crucial step in the regulation of gene expression regulation under normal and pathological conditions that ultimately determines cellular fate. In this context, evidence shows that transfer and ribosomal RNA (tRNA and rRNA) modifications affect the efficacy and fidelity of translation. The number of RNA modifications increases with the complexity of organisms, suggesting an evolutionary diversification of the possibilities for fine-tuning the functions of coding and non-coding RNAs. In this review, we focus on alterations of modifications of transfer and ribosomal RNA that affect translation in human cancer. This variation in the RNA modification status can be the result of altered modifier expression (writers, readers or erasers), but also due to components of the machineries (C/D or H/ACA boxes) or alterations of proteins involved in modifier expression. Broadening our understanding of the mechanisms by which site-specific modifications modulate ribosome activity in the context of tumorigenesis will enable us to enrich our knowledge about how ribosomes can influence cell fate and form the basis of new therapeutic opportunities.

Citing Articles

Epitranscriptomics in the Glioma Context: A Brief Overview.

Santamarina-Ojeda P, Fernandez A, Fraga M Cancers (Basel). 2025; 17(4).

PMID: 40002173 PMC: 11853273. DOI: 10.3390/cancers17040578.


Decoding the molecular script of 2'-O-ribomethylation: Implications across CNS disorders.

Verma A, Roy B, Dwivedi Y Heliyon. 2024; 10(21):e39036.

PMID: 39524798 PMC: 11550049. DOI: 10.1016/j.heliyon.2024.e39036.


Decoding the ribosome's hidden language: rRNA modifications as key players in cancer dynamics and targeted therapies.

Cui L, Zheng J, Lin Y, Lin P, Lu Y, Zheng Y Clin Transl Med. 2024; 14(5):e1705.

PMID: 38797935 PMC: 11128715. DOI: 10.1002/ctm2.1705.


The impact of ribosome biogenesis in cancer: from proliferation to metastasis.

Hwang S, Denicourt C NAR Cancer. 2024; 6(2):zcae017.

PMID: 38633862 PMC: 11023387. DOI: 10.1093/narcan/zcae017.


Heterogeneity of chemical modifications on RNA.

Goh W, Kuang Y Biophys Rev. 2024; 16(1):79-87.

PMID: 38495447 PMC: 10937866. DOI: 10.1007/s12551-023-01128-8.


References
1.
Yi J, Gao R, Chen Y, Yang Z, Han P, Zhang H . Overexpression of NSUN2 by DNA hypomethylation is associated with metastatic progression in human breast cancer. Oncotarget. 2016; 8(13):20751-20765. PMC: 5400542. DOI: 10.18632/oncotarget.10612. View

2.
Park S, Schimmel P, Kim S . Aminoacyl tRNA synthetases and their connections to disease. Proc Natl Acad Sci U S A. 2008; 105(32):11043-9. PMC: 2516211. DOI: 10.1073/pnas.0802862105. View

3.
Penzo M, Montanaro L . Turning Uridines around: Role of rRNA Pseudouridylation in Ribosome Biogenesis and Ribosomal Function. Biomolecules. 2018; 8(2). PMC: 6023024. DOI: 10.3390/biom8020038. View

4.
Shimada K, Nakamura M, Anai S, De Velasco M, Tanaka M, Tsujikawa K . A novel human AlkB homologue, ALKBH8, contributes to human bladder cancer progression. Cancer Res. 2009; 69(7):3157-64. DOI: 10.1158/0008-5472.CAN-08-3530. View

5.
Marcel V, Ghayad S, Belin S, Therizols G, Morel A, Solano-Gonzalez E . p53 acts as a safeguard of translational control by regulating fibrillarin and rRNA methylation in cancer. Cancer Cell. 2013; 24(3):318-30. PMC: 7106277. DOI: 10.1016/j.ccr.2013.08.013. View